Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 585.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 213,431 shares of the company's stock after acquiring an additional 182,314 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.53% of Keros Therapeutics worth $3,379,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after acquiring an additional 46,041 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Keros Therapeutics during the fourth quarter valued at approximately $388,000. Barclays PLC boosted its position in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $461,000. Finally, American Century Companies Inc. grew its stake in shares of Keros Therapeutics by 10.5% in the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock worth $5,207,000 after buying an additional 31,251 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 22.90% of the company's stock.

Analyst Ratings Changes

KROS has been the topic of a number of recent research reports. Piper Sandler cut their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, January 17th. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a report on Thursday, January 16th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. Finally, Wells Fargo & Company lowered their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.33.

Keros Therapeutics Trading Down 1.5 %

KROS stock traded down $0.21 during trading on Friday, reaching $14.21. The stock had a trading volume of 1,003,205 shares, compared to its average volume of 799,227. The firm has a market cap of $576.39 million, a PE ratio of -2.73 and a beta of 1.39. The stock's 50 day moving average is $11.56 and its two-hundred day moving average is $27.87. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. On average, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.